PHILADELPHIA—Phosphorus binding with ferric citrate is associated with lower rates of hospitalization and costs compared with those on sevelamer carbonate or calcium acetate, according to a study presented at Kidney Week 2014.
A team led by Roger A. Rodby, MD, of Rush University Medical Center in Chicago, examined the results from a phase 3 study of 441 end-stage renal disease (ESRD) patients showing that ferric citrate provided similar levels of phosphorus control while increasing iron stores compared to sevelamer carbonate or calcium acetate. Additionally, patients taking ferric citrate required less intravenous iron and erythropoiesis-stimulating agents.
The researchers looked at the rate of serious adverse events in relation to standard billing practices and adjusted for inflation. Medicare payment rates were applied and overall costs were measured per-patient-per-year (PPPY).
Patients treated with ferric citrate had a savings of $896 PPPY for infection-related adverse events, $1,021 PPPY for gastrointestinal-related adverse events, and $1,033 PPPY for cardiac-related adverse events, with lower overall rates of hospitalization in all 3 categories.